Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322714 | 0.97 | KDM4E (0.38) | KDM4EALDH1A1PKMGLAHTT | |
| SCHEMBL6331061 | 0.85 | GPR39 (0.41) | KDM4EALDH1A1PKMHTTNPSR1 | |
| SCHEMBL6328543 | 0.83 | GPR39 (0.39) | KDM4EALDH1A1PKMNPSR1KCNH2 | |
| SCHEMBL6640137 | 0.80 | KMT2A (0.43) | ALDH1A1GLAHTTNPSR1HRH3 | |
| SCHEMBL6322030 | 0.79 | ALDH1A1 (0.52) | KDM4EALDH1A1PKMKCNH2GAA | |
| SCHEMBL6331308 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1PKMGLAHTT | |
| SCHEMBL6322319 | 0.78 | MEN1 (0.37) | — | |
| SCHEMBL6636865 | 0.77 | MEN1 (0.43) | ALDH1A1GLAHTTNPSR1HRH3 | |
| SCHEMBL6329476 | 0.76 | ALDH1A1 (0.49) | KDM4EALDH1A1PKMUSP2KCNH2 | |
| SCHEMBL6324148 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1PKMGLAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-6858616-B2 | Nitrogen containing heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1140871-A4 | THROMBIN OR FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-6500855-B1 | NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6413980-B1 | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-6369227-B1 | BLOOD COAGULATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-09 | — | — | US | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140871-A1 | THROMBIN OR FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |